Patent · US Active

Biomarkers for determining the clinical response to cell therapy

US10746729B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

Tigenix, S.A.U. · ES

Inventors

Olga De La Rosa · Tres Cantos, ES
Wilfried Dalemans · Leuven, BE

Key dates

Filing date	Apr 25, 2016
Grant date	Aug 18, 2020
Priority date	—
Expiry date	Oct 26, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.